Wall Street brokerages expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to post ($0.30) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Amicus Therapeutics’ earnings, with estimates ranging from ($0.39) to ($0.23). Amicus Therapeutics reported earnings per share of ($0.32) in the same quarter last year, which suggests a positive year over year growth rate of 6.3%. The business is expected to report its next earnings report on Wednesday, March 7th.

On average, analysts expect that Amicus Therapeutics will report full year earnings of ($1.52) per share for the current fiscal year, with EPS estimates ranging from ($1.77) to ($1.18). For the next year, analysts expect that the firm will post earnings of ($1.08) per share, with EPS estimates ranging from ($1.65) to ($0.70). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Amicus Therapeutics.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The business had revenue of $10.90 million for the quarter, compared to the consensus estimate of $9.02 million. During the same quarter in the prior year, the company earned ($0.33) earnings per share. Amicus Therapeutics’s quarterly revenue was up 419.0% compared to the same quarter last year.

Several analysts recently weighed in on FOLD shares. Robert W. Baird restated an “outperform” rating and set a $16.00 price objective on shares of Amicus Therapeutics in a research report on Monday, September 25th. Bank of America upped their price objective on Amicus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 4th. Leerink Swann restated a “buy” rating and set a $20.00 price objective (up from $17.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Finally, Chardan Capital restated a “buy” rating and set a $18.50 price objective (up from $16.50) on shares of Amicus Therapeutics in a research report on Thursday, October 5th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Amicus Therapeutics presently has an average rating of “Buy” and a consensus target price of $18.31.

Shares of Amicus Therapeutics (FOLD) opened at $15.07 on Wednesday. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39. Amicus Therapeutics has a 1 year low of $5.07 and a 1 year high of $16.60. The firm has a market capitalization of $2,510.00, a price-to-earnings ratio of -8.23 and a beta of 1.72.

In other Amicus Therapeutics news, Director Donald J. Hayden, Jr. sold 20,000 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $15.00, for a total value of $300,000.00. Following the completion of the transaction, the director now directly owns 25,814 shares in the company, valued at $387,210. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John F. Crowley sold 65,581 shares of the stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $13.51, for a total value of $885,999.31. Following the completion of the transaction, the chief executive officer now owns 393,076 shares of the company’s stock, valued at $5,310,456.76. The disclosure for this sale can be found here. Insiders sold 197,890 shares of company stock valued at $2,767,181 over the last quarter. Corporate insiders own 3.40% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Sage Capital Advisors llc acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at about $154,000. GSA Capital Partners LLP acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at about $309,000. Iguana Healthcare Management LLC acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at about $905,000. Sterling Capital Management LLC acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at about $218,000. Finally, Neuberger Berman Group LLC acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at about $196,000.

TRADEMARK VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/17/zacks-brokerages-anticipate-amicus-therapeutics-inc-fold-will-announce-earnings-of-0-30-per-share.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.